Ju-Ming Huang1, Jin Hu, Ning Chen, Min-Lei Hu. 1. Department of Neurology, The First Hospital of Jia Xing, Jiaxing, 314001, PR China. Electronic address: jiaxingjuminghuang@163.com.
Abstract
PURPOSE: High-mobility group box-1 (HMGB1) is regarded as a central mediator of inflammation and involved in many inflammatory diseases. This study aimed to investigate impact of plasma HMGB1 level on 1-year clinical outcomes of ischemic stroke. METHODS: Plasma HMGB1 levels of 338 patients were quantified by enzyme-linked immunosorbent assay. The end points were mortality and unfavorable outcome (modified Rankin Scale score>2) after 1 year. RESULTS: Plasma HMGB1 level emerged as an independent predictor of 1-year clinical outcomes. Its prognostic value was similar to National Institutes of Health Stroke Scale score's. It improved prognostic value of National Institutes of Health Stroke Scale score. CONCLUSION: Plasma HMGB1 level represents a novel biomarker for predicting 1-year clinical outcomes of ischemic stroke.
PURPOSE:High-mobility group box-1 (HMGB1) is regarded as a central mediator of inflammation and involved in many inflammatory diseases. This study aimed to investigate impact of plasma HMGB1 level on 1-year clinical outcomes of ischemic stroke. METHODS: Plasma HMGB1 levels of 338 patients were quantified by enzyme-linked immunosorbent assay. The end points were mortality and unfavorable outcome (modified Rankin Scale score>2) after 1 year. RESULTS: Plasma HMGB1 level emerged as an independent predictor of 1-year clinical outcomes. Its prognostic value was similar to National Institutes of Health Stroke Scale score's. It improved prognostic value of National Institutes of Health Stroke Scale score. CONCLUSION: Plasma HMGB1 level represents a novel biomarker for predicting 1-year clinical outcomes of ischemic stroke.